NEW YORK (Reuters Health) Jun 04 –
New evidence suggests that health plan sponsors may want to break doctors’ habit of prescribing COX-2 drugs for arthritis, acute pain and other conditions without first having tried less expensive treatments.
The study, released today at the Express Scripts Outcomes Conference, questions the overall cost-effectiveness of COX-2 inhibitors, such as Pharmacia’s Celebrex (celecoxib) and Bextra (valdecoxib) and Merck & Co.’s Vioxx (rofecoxib).
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!